The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...

The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics' drug for treatment of a type of ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally ... for patients with locally advanced or ...

Malignant melanoma is the fastest-growing and 7th ... (which may be pigmented as in acne scars after prolonged minocycline treatment), and seborrheic keratoses. The multidisciplinary team may ...

Sohail Tavazoie and Wenbin Mei, a graduate fellow in the Tavazoie lab. (Credit: Lori Chertoff) Metastasis is the cause of 90 ...

Although patients with metastatic melanoma fare poorly ... determining natural history and outcomes of older melanoma patients following treatment. Immune-based treatment strategies continue ...

A promising breakthrough in the fight against cancer emerges from Russia. The cancer vaccine developed by the Gamaleya Center ...

IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 ...

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...

Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...